Skip to content
MarketScale
‹ Back to IndustriesSciences

Continued Growth in the US and Global Fiber Optics Market

The growth of fiber optics in the US and global market place shows no sign of slowing. Telecommunications and data center enterprises are increasingly turning to fiber as the material of choice for cabling due to its superior performance, cost-effectiveness, durable construction, and scalability. As economies around the globe become digitized, fiber optics are leveraged…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Fiberguide ArticlePromoted Content
Share
Continued Growth in the US and Global Fiber Optics Market

Key takeaways

01

The growth of fiber optics in the US and global market place shows no sign of slowing.

02

Telecommunications and data center enterprises are increasingly turning to fiber as the material of choice for cabling due to its superior performance, cost-effectiveness, durable construction, and scalability.

03

As economies around the globe become digitized, fiber optics are leveraged…

The growth of fiber optics in the US and global market place shows no sign of slowing. Telecommunications and data center enterprises are increasingly turning to fiber as the material of choice for cabling due to its superior performance, cost-effectiveness, durable construction, and scalability. As economies around the globe become digitized, fiber optics are leveraged to bring internet and wireless communications to consumers. Researchers estimate that by 2025 the US fiber market will top $3.56 billion, with the global fiber optics market experiencing annual growth of 5.2% by 2022.[1] Driving this impressive growth is an expanding number of applications for using fiber optics.

Applications

While the use of fiber optics for telecommunications and internet connectivity is well known, those are just two applications for the versatile cabling material. Fiber is incredibly robust and has the ability to withstand high pressure and temperature changes making it ideal for use in the oil & gas industry. Militaries and satellites depend on fiber for remote sensing applications. It is also integrated in laser delivery systems, equipment interconnection, and light conductors utilized by operators in the medical space. Forecasters anticipate that between 2017 and 2021 the global distributed fiber optics sensing market will experience a compound annual growth rate of 8.55%.[2]

Fiber Optic Security Systems Market

High value and sensitive physical sites have long been targets for theft and terrorism. To lower the risk of intrusion, a fiber optic perimeter security system is a way of augmenting securing and monitoring these sites. The system is suitable for both commercial and residential use, and reduces human labor requirements when compared to traditional perimeter security systems. Researchers predict North America will capture the largest share of the growing fiber optic perimeter security market.

Meeting Demand

The amount of applications using fiber is prompting fiber optics manufacturers to release industry-specific products capable of meeting the specific demands of enterprise customers. Experts predict that industrial usage will emerge as the fastest growing segment, while the cable installers segment will grab the highest market share with home and building connectivity dominating the fiber space. As residential homes become more connected and transform into smart homes, demand for fiber optics will only propel higher. Government initiatives to bring connectivity to underserved areas is also expected to contribute to fiber proliferation.

Institutional investors are finding that there are numerous opportunities to take part in the booming fiber optics market. At Fiberguide, we’re helping meet the growing demand by manufacturing efficient, cost-effective and customizable fiber optic solutions for OEM manufacturers. Take the time to learn about our cutting-edge innovations.

https://www.fiberguide.com/wp-content/uploads/2018/08/AdobeStock_27095637.jpeg[1] https://www.hexaresearch.com/press-release/us-fiber-optics-market-analysis

[2] https://www.giiresearch.com/report/infi560891-global-distributed-fiber-optic-sensing-market.html

Read more at fiberguide.com

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512